The invention relates to an
SPECT imaging agent for FAP-alpha specific tumor diagnosis. The
imaging agent is formed by taking a micromolecular FAP-alpha inhibitor of a modified N-4-quinolyl-
glycine-(2S)-cyanoproline skeleton as a precursor compound, taking 99mTc as
radionuclide and taking N-
tris (
hydroxymethyl) methylglycine (
Tricine) and
triphenylphosphine tri-m-
sodium sulfonate (TPPTS) as synergistic ligands. Compared with the prior art, the
imaging agent has high sensitivity, more excellent in-vivo biological distribution is shown, compared with the prior art, the complex has the advantagesof higher tumor uptake and tumor / organ uptake ratio, more stable coordination property, and excellent in-vivo and in-vitro stability. Due to the obvious coordination structure characteristics of theimaging agent, a one-step marking kit technology can be used, and the
imaging agent has better
druggability and is suitable for industrial production and clinical popularization.